INDIVIDUAL TEST 450
RNA Polymerase Antibodies
Indication
Suspicion of systemic sclerosis
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: cold
Method
ELISA-based technique (EliA)
Reference interval
<7 U/mL negative, 7-<10 U/mL borderline
Result
Results are reported as negative, borderline or positive with a concentration (U/mL).
Interpretation
Antibodies directed against RNA polymerases serve as important serological markers for systemic sclerosis (SSc) and are detectable in approximately 20% of affected individuals. Anti-RNA polymerase I antibodies, and particularly anti-RNA polymerase III antibodies, exhibit a strong association with diffuse cutaneous systemic sclerosis and correlate with an increased risk of internal organ involvement. These antibodies may also occur in systemic sclerosis overlap syndromes and have been reported, albeit rarely, in cases of systemic lupus erythematosus (SLE). Antibodies against RNA polymerase II are frequently detected in conjunction with antibodies against RNA polymerases I and III. The presence of anti-RNA polymerase III antibodies is highly indicative of diffuse systemic sclerosis and is associated with a more aggressive disease course and significant internal organ involvement.
References
- Elhannani A et al. Rheumatology (Oxford). 2025. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis. PMID: 40676730
- Hesselstrand R et al. Rheumatology (Oxford). 2003. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. PMID: 12649400
- Andraos R et al. Lupus Sci Med. 2022. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis. PMID: 36581379
Last updated: 2025-12-01
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 450
RNA Polymeras-antikroppar
Indikation
Misstanke om systemisk skleros
Provmaterial
Serum
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: rumstemperatur
- Internationellt: kylt
Metod
ELISA-baserad teknik (EliA)
Referensintervall
<7 U/mL negativt, 7-<10 U/mL gränsvärde
Resultat
Resultatet anges som negativt, gränsvärde eller positivt med koncentration (U/mL).
Tolkning
Antikroppar mot RNA polymeras är markörer för systemisk skleros och kan påvisas hos ca 20% av patienterna. Anti-RNA Polymeras I och framförallt anti-RNA polymeras III har hög association till diffus systemisk skleros och är associerat med ökad risk för inre organ engagemang. Antikropparna kan även ses vid systemisk skleros-överlappningssyndrom och har rapporterats förekomma i enstaka fall med SLE. Antikroppar mot RNAP II påvisas ofta tillsammans med antikroppar mot RNAP I och III. Antikroppar mot RNAP III talar starkt för systemisk skleros av diffus typ och är associerade med snabbt förlopp och inre organengagemang.
Referenser
- Elhannani A et al. Rheumatology (Oxford). 2025. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis. PMID: 40676730
- Hesselstrand R et al. Rheumatology (Oxford). 2003. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. PMID: 12649400
- Andraos R et al. Lupus Sci Med. 2022. Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis. PMID: 36581379
Senast uppdaterat: 2025-12-01